Geron Corporation (NASDAQ:GERN) Experiences Heavy Trading Volume

Postado Novembro 14, 2017

However a year ago for the same quarter the company has reported $-0.05 EPS.

Analysts expect Geron Corporation (GERN) to generate earnings per share of $0.17 in 2017. The company had revenue of $0.16 million during the quarter, compared to analysts' expectations of $0.40 million. During the same period in the prior year, the business posted $0.17 earnings per share. Volume was up 113.64% over the stocks average daily volume. Geron Corporation's revenue for the quarter was down 96.8% on a year-over-year basis.

Additionally on 12/17/15 Janney Capital "Initiates Coverage on" Geron Corporation (NASDAQ:GERN) to Buy setting price target at $6.5 and on 4/21/15 Oppenheimer "Initiates Coverage on" the stock to Outperform at $5.5.

GERN has been the subject of a number of other research reports. If the published price targets set by Fred's, Inc. analysts have any power to influence the stock's share price, the highest price target set for FRED is $12.

Geron Corporation (NASDAQ:GERN)'s stock had its "hold" rating reaffirmed by investment analysts at Needham & Company LLC in a note issued to investors on Friday, November 3rd. BidaskClub downgraded shares of Geron Corporation from a "hold" rating to a "sell" rating in a research report on Saturday, August 5th. The average investment rating for GERN on a scale of 1 to 5 (1 being a strong sell and 5 being a strong buy) is a 4.00 or a Moderate Buy. If you are reading this article on another publication, it was illegally copied and reposted in violation of worldwide copyright and trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/13/geron-corporations-gern-hold-rating-reaffirmed-at-stifel-nicolaus.html.

A number of large investors have recently made changes to their positions in GERN. Ubs Asset Management Americas Inc owns 1,455 shares with a value of $3,172,000. Zacks Investment Research downgraded shares of Geron Corporation from a "buy" rating to a "hold" rating in a research report on Tuesday, October 10th. Parametric Portfolio Associates LLC raised its stake in shares of Geron Corporation by 59.4% in the second quarter. BlackRock Investment Management LLC now owns 590,291 shares of the biopharmaceutical company's stock valued at $1,582,000 after buying an additional 22,485 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Geron Corporation by 26.5% in the first quarter. Tudor Investment Corp ET AL now owns 52,369 shares of the biopharmaceutical company's stock worth $119,000 after acquiring an additional 5,669 shares in the last quarter.

Geron Corporation (Geron), launched on November 28, 1990, is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.